Table 5 Annual number of visits to health care professionals (excluding visits for administration)
From: Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
Agent | Hospital | Dermatologist’s private office | GP’s private office |
|---|---|---|---|
Adalimumab | 6 | 5 | 2 |
Etanercept | 6 | 5 | 2 |
Infliximab | 5 | 2 | 0 |
Ustekinumab | 6 | 4 | 1 |